Cardiol Therapeutics Inc Class A (CRDL : TSX)
Common Stock
$1.57
CAD
-0.04 (-2.48%)
Last updated: 2026-06-05
CRDL
Cardiol Therapeutics Inc Class A
WealthAwesomePerformance
1 Day
-2.48%
1 Week
-7.10%
1 Month
-13.74%
YTD
+15.44%
Key Statistics
Market Cap
$180.98M
52W High
$2.33
52W Low
$1.23
P/E Ratio
-
50 Day MA
$1.83
200 Day MA
$1.54
Beta
0.42
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/5/2026 | $1.58 | $1.60 | $1.54 | $1.57 | $1.57 | 38,983 |
| 6/4/2026 | $1.55 | $1.62 | $1.52 | $1.61 | $1.61 | 26,540 |
| 6/3/2026 | $1.60 | $1.60 | $1.53 | $1.55 | $1.55 | 47,095 |
| 6/2/2026 | $1.68 | $1.68 | $1.60 | $1.63 | $1.63 | 122,682 |
| 6/1/2026 | $1.68 | $1.75 | $1.67 | $1.69 | $1.69 | 49,046 |
| 5/29/2026 | $1.77 | $1.77 | $1.68 | $1.69 | $1.69 | 45,965 |
| 5/28/2026 | $1.79 | $1.80 | $1.76 | $1.79 | $1.79 | 23,871 |
| 5/27/2026 | $1.80 | $1.83 | $1.75 | $1.78 | $1.78 | 47,997 |
| 5/26/2026 | $1.80 | $1.86 | $1.80 | $1.81 | $1.81 | 69,503 |
| 5/25/2026 | $1.86 | $1.89 | $1.84 | $1.85 | $1.85 | 9,671 |
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 282.2% over the next 12 months.
Consensus
No RatingAvg. Target
C$6.00
+282.2% Upside
Current Price
C$1.57
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
40.1%
Annualized
90-Day Vol
62.7%
Annualized
Trend (90d)
+27.6%
Annualized drift
90d Mean
C$1.73
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.62 | C$1.41 โ C$1.86 |
| 60 trading days | C$1.68 | C$1.38 โ C$2.04 |
| 90 trading days | C$1.73 | C$1.36 โ C$2.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-35.55M
- Profit Margin
- 0.00%
- ROE (TTM)
- -173.96%
- EPS (Diluted)
- -0.39
- Book Value
- 0.22
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CRDL
Articles Featuring CRDL.TO
Latest articles and analysis covering CRDL.TO
